Reference:
[1]. Nobuko Hijiya1 and Meinolf Suttorp2. How I treat
chronic myeloid leukemia in children and adolescents. Blood.
2019;133(22):2374-2384.
[2]. J.-M. Cayuela1, F. Huguet2 Le diagnostic de la
leucémie myéloïde chronique (LMC) en 2012. Oncologie (2012) 14:
561–568.
[3]. Sebastian Kreil, 1,2 Markus Pfirrmann, 3,4 Claudia
Haferlach, 5 et al. Heterogeneous prognostic impact of derivative
chromosome 9 deletions in chronic myelogenous leukemia,
Blood (2007) 110 (4): 1283–1290.
[4]. Elias Jabbour,
Hagop Kantarjian, Susan
O’Brien, et al. Cortes Predictive factors for
outcome and response in patients treated with second-generation tyrosine
kinase inhibitors for chronic myeloid leukemia in chronic phase after
imatinib failure. Blood (2011) 117 (6): 1822–1827.
[5]. Baccarani M, Saglio G, Goldman J, et al. (2006)
Evolving concepts in the management of chronic myeloid leukemia:
recommendations from an expert panel on behalf of the European
LeukemiaNet. Blood 108: 1809–20.
[6]. Meyran, Deborah. ”Leucémie myéloïde chronique chez
l’enfant, une pathologie rare et unique.” Médecine
thérapeutique/Pédiatrie 22.2 (2019): 108-116.
[7].Jean-MichelCayuela12Jean
ClaudeChomel12ValérieCoiteux1,
et al. Recommendations from the French CML Study Group (Fi-LMC)
for BCR-ABL1 kinase domain mutation analysis in chronic myeloid
leukemia.
Bulletin
du Cancer,
Volume
107, Issue 1, January 2020, Pages 113-128.